Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy
Time: 4:15 pm
day: Conference Day One
Details:
Illustrating the concept, design and preclinical validation of tumor-activated IL-2 and IL-12 INDUKINE molecules
Demonstrating that a prodrug strategy permits systemic dosing of wild type cytokines at exposures required for monotherapy activity
Integrating clinical safety, efficacy, PK and tumor biomarker data to establish POC for novel cytokine engineering strategies in FIH studies
